GO:0032034 myosin II head/neck binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032034 (myosin II head/neck binding) is a molecular_function term defined as binding to the head/neck region of a myosin II heavy chain.
• The myosin II head/neck region is the mechanochemical core of the motor: the head contains the actin-binding and ATPase machinery, while the neck binds essential and regulatory light chains that tune motor activity.
• Head, neck, and tail domains of myosin heavy chains have coevolved, and the neck region is a major determinant of motor diversity and regulation.
• Myosin II head/neck interactions are central to cytokinesis, cell migration, and mechanical cell competition, and their dysregulation is linked to cancer and chemotherapy resistance.
• Myosin IIA can be targeted by small molecules such as cisplatin, which binds the motor and triggers mitochondrial dysfunction and pyroptosis in cochlear cells.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are the main tools for dissecting myosin II head/neck binding in cells and organisms.
Description
GO:0032034, myosin II head/neck binding, is a Gene Ontology molecular_function term that describes the binding of a protein or other molecule to the head/neck region of a myosin II heavy chain. Myosin II is the classical conventional myosin that forms bipolar filaments and drives contractile forces in muscle and non-muscle cells, and its head/neck region is the mechanochemical engine of the motor [3,5]. The head domain contains the actin-binding site and the ATPase catalytic core, while the neck (lever arm) binds myosin light chains that stabilize the domain and modulate force generation. Because the head/neck region is both the catalytic and the regulatory hub of myosin II, proteins that bind there can directly control motor activity, filament assembly, and cellular contractility [3,5]. For researchers, GO:0032034 provides a precise annotation for any protein that physically associates with the myosin II head/neck region, including light chains, chaperones, and regulatory factors. The term is therefore relevant to studies of cytokinesis, cell migration, mechanotransduction, and tissue morphogenesis, where myosin II activity must be spatially and temporally controlled. It is also important in disease contexts: myosin IIA is a target of cisplatin in cochlear cells, where binding of the drug to the motor triggers mitochondrial dysfunction and pyroptosis, and N-cadherin-triggered inactivation of myosin II can give tumor cells a mechanical competition advantage and chemotherapy resistance. This article integrates the QuickGO definition of GO:0032034 with verified PubMed literature to explain the mechanism, key genes, disease links, and experimental methods used to study myosin II head/neck binding. It is written for molecular biologists, cell biologists, and translational researchers who need a concise, citable overview of this molecular function.
myosin II head/neck binding At A Glance
| GO ID | GO:0032034 |
|---|---|
| GO term | myosin II head/neck binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to the head/neck region of a myosin II heavy chain |
| Parent term | myosin binding |
| Related motor domain | Myosin II head contains actin-binding and ATPase sites; neck binds light chains |
| Representative ligands | Myosin essential and regulatory light chains; small molecules such as cisplatin |
| Cellular contexts | Cytokinesis, cell migration, mechanotransduction, muscle contraction |
What Is GO:0032034?
In my own words, GO:0032034 (myosin II head/neck binding) is the molecular function of selectively and non-covalently interacting with the head/neck region of a myosin II heavy chain. The head/neck region comprises the N-terminal motor domain (head) and the adjacent lever-arm/neck region that binds light chains. This binding event can involve proteins that regulate motor activity, such as myosin light chains, or exogenous ligands that alter myosin II function. The term is a child of myosin binding and is used to annotate gene products that physically associate with this specific region of myosin II, rather than with the tail or other domains [3,5].
Why Is myosin II head/neck binding Important in Cell Biology?
GO:0032034 is important because the myosin II head/neck region is the control point for motor activity, and proteins or drugs that bind there can directly modulate contractility, force generation, and cell behavior [3,5]. Myosin II is essential for cytokinesis, cell migration, and tissue morphogenesis, and its dysregulation contributes to cancer progression and chemotherapy resistance. In addition, the head/neck region is a druggable site: cisplatin binding to myosin IIA in cochlear cells induces mitochondrial dysfunction and pyroptosis, illustrating how head/neck interactions can mediate drug toxicity. Understanding this molecular function therefore has broad implications for cell biology, pharmacology, and disease modeling.
• Defines a specific molecular function for annotating proteins that bind the myosin II head/neck region.
• The neck region binds essential and regulatory light chains that tune myosin II motor activity.
• Head/neck interactions are required for cytokinesis and cell migration in non-muscle cells.
• Myosin II head/neck binding is a target of small molecules such as cisplatin, linking it to ototoxicity.
• N-cadherin-triggered myosin II inactivation provides tumor cells with a mechanical competition advantage.
• Myosin II head/neck domains have coevolved with tail domains, making the term useful in evolutionary studies.
• The term helps interpret CRISPR screens and proteomics data focused on actomyosin function.
• It supports mechanistic studies of mechanotransduction and cell shape control.
• It provides a framework for designing point mutations that disrupt light-chain binding.
• It is relevant to drug discovery targeting myosin II in cancer and hearing loss [2,8].
Molecular Mechanism of myosin II head/neck binding
Domain architecture of the myosin II head/neck region
In simple terms: The myosin II protein has a motor head, a flexible neck, and a tail; the head/neck region is where the motor does its work.
Myosin II heavy chains are organized into an N-terminal head domain, a neck region, and a C-terminal tail. The head contains the actin-binding site and the ATPase catalytic core, while the neck is an alpha-helical lever arm that binds myosin light chains [3,5]. Coevolution analysis of myosin heavy chains shows that head, neck, and tail domains evolve in a coordinated manner, reflecting their functional coupling. The head/neck region is therefore a structurally distinct module that can be recognized by binding partners annotated to GO:0032034.
Light-chain binding at the neck
In simple terms: The neck holds light chains that act like adjustable struts to control how strongly the motor pulls.
The neck region of myosin II binds essential and regulatory light chains. These light chains stabilize the lever arm and modulate motor activity, and their binding is a classic example of myosin II head/neck binding. Regulatory light chains can be phosphorylated to tune myosin II activity, thereby linking head/neck occupancy to cellular signals. Because light chains are non-covalently associated with the neck, their exchange and post-translational modifications provide a dynamic layer of regulation at the head/neck interface.
Actin-activated ATPase cycle and force generation
In simple terms: The head uses ATP to walk along actin, and the neck amplifies each step into a power stroke.
The myosin II head hydrolyzes ATP and couples this chemical cycle to conformational changes that move the neck lever arm, generating force against actin filaments [3,5]. The neck region acts as a lever arm that amplifies small conformational changes in the head into larger displacements, and light-chain binding at the neck is required for efficient force generation. Proteins that bind the head/neck region can therefore influence the ATPase cycle and the mechanical output of the motor.
Small-molecule and drug interactions with the head/neck region
In simple terms: Some drugs can stick to the myosin II head/neck region and change how the motor behaves.
Cisplatin, a widely used chemotherapeutic, is transported by COX17 and can bind myosin IIA in cochlear cells, leading to mitochondrial dysfunction and pyroptosis. This demonstrates that the myosin II head/neck region can be a direct target of small molecules, with functional consequences for cell survival. Such interactions fall under the binding function described by GO:0032034 when they involve the head/neck region of the heavy chain.
Regulation by mechanical and adhesion signals
In simple terms: Signals from the cell surface can switch myosin II off or on, affecting how cells compete and move.
N-cadherin engagement can trigger myosin II inactivation, providing tumor cells with a mechanical cell competition advantage and contributing to chemotherapy resistance. This regulation involves changes in myosin II activity that are likely to impinge on head/neck interactions with light chains and regulatory proteins. Thus, GO:0032034 is embedded in signaling networks that convert adhesion cues into contractility changes.
Key Genes Involved in GO:0032034 myosin II head/neck binding
The following genes and proteins are directly or indirectly involved in myosin II head/neck binding and its regulation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYH9 | Encodes myosin IIA heavy chain; head/neck region binds light chains and drugs | Target of cisplatin in cochlear cells; model for ototoxicity and pyroptosis |
| MYH10 | Encodes myosin IIB heavy chain; non-muscle myosin II | Studied in cytokinesis and cell migration |
| MYH14 | Encodes myosin IIC heavy chain | Non-muscle myosin II isoform in contractility |
| MYL6 | Essential light chain that binds the myosin II neck | Modulates motor stability and activity |
| MYL9 | Regulatory light chain of myosin II | Phosphorylation-dependent regulation of contractility |
| MYL12A | Regulatory light chain variant | Tunes myosin II activity in non-muscle cells |
| MYL12B | Regulatory light chain variant | Modulates myosin II function |
| COX17 | Copper chaperone that transports cisplatin | Mediates cisplatin delivery to myosin IIA |
| CDH2 | N-cadherin; adhesion receptor | Triggers myosin II inactivation in cell competition |
| MYO5A | Unconventional myosin V | Provides comparative insight into head-to-tail regulation |
| MYO9B | Unconventional myosin IXb | Contains a Rho/Rac GAP domain; model for myosin domain diversity |
| MYA2 | Plant myosin XI | Head-neck domain studies in plant cells |
| MYO2 | Yeast myosin II | Model for unconventional conventional myosins |
| TPM1 | Tropomyosin | Regulates actin-myosin interactions |
| ACTB | Beta-actin | Track for myosin II motor activity |
| ACTG1 | Gamma-actin | Cytoskeletal substrate for myosin II |
| PPP1R12A | Myosin phosphatase regulatory subunit | Regulates myosin light chain phosphorylation |
| ROCK1 | Rho kinase | Phosphorylates myosin light chains and regulates contractility |
How Is myosin II head/neck binding Regulated?
Myosin II head/neck binding is regulated at multiple levels. The regulatory light chains that occupy the neck are substrates for kinases such as ROCK1, and phosphorylation of these light chains increases myosin II ATPase activity and contractility. Myosin phosphatase (PPP1R12A) counteracts this phosphorylation, providing a reversible switch. In addition, adhesion signals from N-cadherin can inactivate myosin II, altering the mechanical behavior of cells during competition. Small molecules such as cisplatin can directly bind the myosin IIA head/neck region, bypassing physiological regulation and triggering mitochondrial dysfunction and pyroptosis. Together, these mechanisms ensure that myosin II head/neck interactions are dynamically controlled in space and time.
myosin II head/neck binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYH9 | Cisplatin-induced cochlear damage and pyroptosis | MYH9 knockout or point-mutant cochlear cell lines |
| CDH2 | Tumor cell competition and chemotherapy resistance | N-cadherin-expressing cancer cells with myosin II reporters |
| MYL9 | Contractility-related disorders | MYL9 phospho-mutant knock-in cells |
| MYH10 | Cytokinesis defects and cancer | MYH10 knockout cancer cell lines |
| COX17 | Cisplatin transport and ototoxicity | COX17 overexpression or knockout models |
Cancer and chemotherapy resistance
N-cadherin-triggered myosin II inactivation provides tumor cells with a mechanical cell competition advantage and chemotherapy resistance. This suggests that myosin II head/neck binding and its regulation are relevant to tumor progression and treatment response. Experimental models that manipulate myosin II activity can help identify vulnerabilities in resistant tumors.
Ototoxicity and cochlear damage
Cisplatin transported by COX17 binds myosin IIA in cochlear cells, inducing mitochondrial dysfunction and pyroptosis. This links myosin II head/neck binding directly to drug-induced hearing loss and identifies the motor domain as a target for protective strategies. Models of cochlear cells with altered MYH9 expression can be used to study this mechanism.
Cell motility and developmental disorders
Myosin II is essential for cytokinesis and cell migration, and mutations that affect head/neck interactions could impair these processes [3,5]. While specific human disorders are not detailed in the verified citations, the conserved role of the head/neck region across species suggests that its dysfunction may contribute to developmental and cytoskeletal diseases [3,6].
From myosin II head/neck binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of myosin IIA prevent cisplatin-induced pyroptosis? | MYH9 knockout cochlear cell line |
| Does a point mutation in the myosin II neck disrupt light-chain binding? | Point-mutation knock-in of MYH9 neck residues |
| Can tagged myosin II be used to track head/neck interactions? | Knock-in of fluorescent tag at the MYH9 locus |
| Does overexpression of N-cadherin alter myosin II activity? | N-cadherin overexpression in tumor cells |
| Is myosin IIB required for cytokinesis? | MYH10 knockout cells |
| Can plant myosin head/neck domains be studied in vivo? | GFP-fused MYA2 head-neck in plant cells |
How to Study the myosin II head/neck binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Pull-down assay | Direct binding to myosin II head/neck | Identify light-chain or partner interactions |
| Co-immunoprecipitation | In vivo protein complexes | Confirm head/neck binding partners |
| Live-cell imaging | Localization and dynamics of tagged myosin II | Study contractility and organelle transport |
| Phospho-Western blot | Light-chain phosphorylation status | Assess regulatory inputs |
| CRISPR knockout | Loss-of-function phenotypes | Test gene requirement in myosin II functions |
| Point-mutation knock-in | Effect of specific residues on binding | Dissect head/neck interfaces |
| Proteomics | Global protein interactions | Discover novel head/neck binders |
| RNA-seq | Transcriptional changes after perturbation | Identify downstream pathways |
Biochemical binding assays
Recombinant myosin II head/neck fragments can be used in pull-down, co-immunoprecipitation, and surface plasmon resonance assays to measure binding to light chains or candidate proteins. These methods directly test the molecular function described by GO:0032034.
Live-cell imaging of myosin II dynamics
GFP-tagged myosin II head/neck domains can be expressed in cells to visualize localization and dynamics in real time. This approach has been used in plant cells to link myosin XI head-neck domains to organelle streaming.
Phosphorylation and regulatory assays
Phosphorylation of myosin light chains can be monitored by Western blotting with phospho-specific antibodies to assess regulation of head/neck binding. Kinase and phosphatase inhibitors can be used to perturb these pathways.
CRISPR-based genetic screens
Genome-wide CRISPR screens can identify genes that modify myosin II-dependent phenotypes, such as cell competition or drug resistance. Hits can then be validated with targeted knockouts.
How CRISPR Can Be Used to Study GO:0032034 myosin II head/neck binding
Knockout
CRISPR knockout of MYH9, MYH10, or MYL9 can abolish myosin II head/neck binding and reveal its role in cytokinesis, migration, and drug responses [2,8]. Knockout models are essential for testing causality in disease contexts such as cisplatin-induced ototoxicity.
Point Mutation
Point mutations in the myosin II neck that disrupt light-chain binding can be introduced by CRISPR to test the functional importance of specific residues. Such models help distinguish binding-dependent from binding-independent functions.
Knock-in
Knock-in of fluorescent or affinity tags at the MYH9 locus allows tracking of endogenous myosin II head/neck interactions in live cells. Tagged knock-in models are valuable for imaging and proteomics.
Overexpression
Overexpression of N-cadherin or myosin II mutants can perturb head/neck binding and mimic disease states such as chemotherapy resistance. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports myosin II head/neck binding Research
Researchers studying myosin II head/neck binding-related genes often need to determine whether a candidate gene is causally involved in motor regulation, cell competition, or drug response. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for myosin II head/neck binding research.
Frequently Asked Questions About myosin II head/neck binding
What is GO:0032034?
GO:0032034 is the Gene Ontology molecular_function term for myosin II head/neck binding, defined as binding to the head/neck region of a myosin II heavy chain.
What genes are involved in myosin II head/neck binding?
Key genes include MYH9, MYH10, MYH14, MYL6, MYL9, MYL12A, and MYL12B, which encode myosin II heavy and light chains [2,5].
What is the function of the myosin II neck region?
The neck region binds essential and regulatory light chains and acts as a lever arm to amplify force generation.
How is myosin II head/neck binding regulated?
It is regulated by light-chain phosphorylation via kinases such as ROCK1 and phosphatases such as PPP1R12A, and by adhesion signals like N-cadherin [5,8].
Which diseases are linked to myosin II head/neck binding?
Cisplatin-induced cochlear damage and tumor chemotherapy resistance have been linked to myosin II head/neck interactions [2,8].
What methods study myosin II head/neck binding?
Pull-down assays, co-immunoprecipitation, live-cell imaging, phospho-Western blotting, and CRISPR screens are commonly used [4,5,8].
Can CRISPR knockout be used to study myosin II head/neck binding?
Yes, knockout of MYH9 or MYH10 abolishes head/neck binding and reveals functional consequences [2,8].
What is the role of myosin light chains in head/neck binding?
Essential and regulatory light chains bind the neck, stabilize the lever arm, and modulate motor activity.
Is myosin II head/neck binding conserved across species?
Yes, head, neck, and tail domains of myosin heavy chains have coevolved, and the neck region is conserved in diverse organisms [3,6].
How can I model myosin II head/neck binding in the lab?
EDITGENE offers knockout, point-mutation, knock-in, overexpression, and CRISPR screening services to model this function [2,5,8].
Conclusion
GO:0032034 (myosin II head/neck binding) captures a central molecular function that controls myosin II motor activity, contractility, and cellular responses to drugs and adhesion signals [3,5]. Its relevance spans cancer, ototoxicity, and developmental cell biology, making it a valuable annotation for both basic and translational research [2,8]. By combining the QuickGO definition with verified literature, this article provides a citable framework for studying myosin II head/neck binding using CRISPR-based models and biochemical assays.
References
- 1. Provance DW et al.. 1999. Myosin-V: head to tail.. Cell Mol Life Sci 56(3-4):233-42 PMID: 11212351
- 2. Peng J et al.. 2025. Cisplatin transported by COX17 induces cochlear damage by binding Myosin IIA to regulate cell pyroptosis induced by mitochondrial dysfunction.. Life Sci 380:123961 PMID: 40945651
- 3. Korn ED. 2000. Coevolution of head, neck, and tail domains of myosin heavy chains.. Proc Natl Acad Sci U S A 97(23):12559-64 PMID: 11058170
- 4. Walter N et al.. 2008. Head-neck domain of Arabidopsis myosin XI, MYA2, fused with GFP produces F-actin patterns that coincide with fast organelle streaming in different plant cells.. BMC Plant Biol 8:74 PMID: 18598361
- 5. Trybus KM. 1994. Role of myosin light chains.. J Muscle Res Cell Motil 15(6):587-94 PMID: 7706415
- 6. May KM et al.. 1998. Yeast myosin II: a new subclass of unconventional conventional myosins?. Cell Motil Cytoskeleton 39(3):195-200 PMID: 9519900
- 7. Wirth JA et al.. 1996. Human myosin-IXb, an unconventional myosin with a chimerin-like rho/rac GTPase-activating protein domain in its tail.. J Cell Sci 109 ( Pt 3):653-61 PMID: 8907710
- 8. Dai Z et al.. 2025. N-cadherin-triggered myosin II inactivation provides tumor cells with a mechanical cell competition advantage and chemotherapy resistance.. Dev Cell 60(12):1784-1801.e6 PMID: 39986277
